Intelligence Β· Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors β phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β searchable for business development and competitive intelligence.
-
LEE011, TMT212, Mekinist 2 mg film-coated tablets, Mekinist 0.5 mg film-coated tablets, TMT212, JDQ443, CETUXIMAB
Novartis Pharmaceuticals
Adult patients with advanced (metastatic or unresectable) KRAS G12C mutant solid tumors
1 trial -
LENVIMA 4 mg hard capsules
Pari Pharma GmbH
Non-resectable hepatocellular carcinoma (HCC)
1 trial -
LENVIMA 4 mg hard capsules
Pari Pharma GmbH
Patients with Biopsy-proven or radiologically-suggested BCLC A HCC eligible for PA and comprising at least one of the following criteria: - Single tumour>3 cmβ€ 5cm or - multiple tumours (max 3 lesions β€ 3cm) or - Single tumour between 2 and 3 cm with at least one of the following characteristic: β’ Serum AFP>100 ng/mL β’ Infiltrative form β’ Macro-trabecular subtype (if applicable)
1 trial -
LEO 90105
LEO Pharma A/S
Psoriasis Vulgaris
1 trial -
LEUPRORELIN ACETATE, FULVESTRANT, ECI830, GOSERELIN, LEUPRORELIN ACETATE, GOSERELIN, RIBOCICLIB, ECI830, ECI830
Novartis Pharmaceuticals
Advanced solid tumors, Advanced HR+/HER2- breast cancer
1 trial -
LEUPRORELIN ACETATE, LETROZOLE, GVV858, LEUPRORELIN ACETATE, FULVESTRANT, GVV858, GOSERELIN, GOSERELIN
Novartis Pharmaceuticals
Advanced HR+/HER- breast cancer
1 trial -
LGD-6972-5 mg
LIGAND PHARMACEUTICALS INC
Type 2 Diabetes Mellitus
1 trial -
LIBTAYO 350 mg concentrate for solution for infusion., Fianlimab
Lacuna Pharma Pty Ltd
Melanoma
1 trial -
LIBTAYO 350 mg concentrate for solution for infusion., LIBTAYO 350 mg concentrate for solution for infusion., LIBTAYO 350 mg concentrate for solution for infusion., LIBTAYO 350 mg concentrate for solution for infusion., REGN10597
Lacuna Pharma Pty Ltd
Melanoma, Advanced Solid Tumours, Clear-Cell Renal-Cell Carcinoma (ccRCC)
1 trial -
LIBTAYO 350 mg concentrate for solution for infusion., Vidutolimod, Vidutolimod
Lacuna Pharma Pty Ltd
Advanced or Metastatic Cancer Merkel Cell Carcinoma (MCC) Cutaneous Squamous Cell Carcinoma (CSCC) Basal Cell Carcinoma (BCC) Triple Negative Breast Cancer (TNBC) Non-Small Cell Lung Cancer (NSCLC)
1 trial -
LIK066
Novartis Pharmaceuticals
Obese Patients With Non-alcoholic Steatohepatitis (NASH)
1 trial -
LISINOPRIL , XXB750, AZILSARTAN MEDOXOMIL , CANDESARTAN , BENAZEPRIL , TRANDOLAPRIL , FOSINOPRIL , PERINDOPRIL , MOEXIPRIL , QUINAPRIL , CAPTOPRIL , EPROSARTAN , RAMIPRIL , IRBESARTAN , VALSARTAN AND SACUBITRIL , ZOFENOPRIL , CILAZAPRIL , DELAPRIL , OLMESARTAN MEDOXOMIL , IMIDAPRIL , 0 mg/1 mL Placebo to XXB750 150 mg/1 mL concentrate for solution for injection, ENALAPRIL , TELMISARTAN , VALSARTAN , LOSARTAN
Novartis Pharmaceuticals
Heart Failure
1 trial -
LNA043
Novartis Pharmaceuticals
Osteoarthritis
1 trial -
LOU064, -, -, Placebo to LOU064 Film-coated tablet
Novartis Pharmaceuticals
Chronic Inducible urticaria and Chronic Spontaneous Urticaria
1 trial -
LP-08 80mg
LIPELLA PHARMACEUTICALS INC.
Interstitial Cystitis
1 trial -
LP-10
LIPELLA PHARMACEUTICALS INC.
Hemorrhagic Cystitis
1 trial -
LP-10 (Liposomal Tacrolimus)
LIPELLA PHARMACEUTICALS INC.
Oral Lichen Planus
1 trial -
LTP001, Placebo to LTP001 1mg and 5mg hard gelatin capsules, LTP001
Novartis Pharmaceuticals
Idiopathic pulmonary fibrosis
1 trial -
LUM001
Mirum Pharmaceuticals International B.V.
Primary Sclerosing Cholangitis (PSC)
1 trial -
LUM001
Mirum Pharmaceuticals International B.V.
Primary Biliary Cirrhosis
1 trial -
LUM001
Mirum Pharmaceuticals International B.V.
PBC
1 trial -
LUM001
Mirum Pharmaceuticals International B.V.
Alagille Syndrome
2 trials -
LUM001 (Maralixibat)
Mirum Pharmaceuticals International B.V.
Progressive Familial Intrahepatic Cholestasis (PFIC)
1 trial -
LUM001 (Maralixibat)
Mirum Pharmaceuticals International B.V.
Alagille Syndrome
3 trials
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1β3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources